GlaxoSmithKline and Gilead Sciences release:* First-line combination of ambrisentan and tadalafil reduces risk of clinical failure compared to monotherapy in pulmonary arterial hypertension outcomes study* Plan to seek approval for this combination indication by submitting data from Ambition study to regulators* GSK and Gilead jointly sponsored studynnFurther company coverage: nn (Reporting by Ben Hirschler)